Applied Therapeutics Takes Action Against Fraudulent “Short Report”

NEXT STORY
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate   
PREV STORY
Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Biocartis Group NV: Study Reviewing 2,500 Performed Idylla(TM) Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

PRESS RELEASE: 27 June 2018, 07:00 CEST Study Reviewing 2,500 Performed Idylla(TM) Tests Shows Generation ...

author_avatar
NASDAQ Market News

Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine

– Marked and Durable Responses Across TRK Fusion Cancers – – 75 Percent Overall ...

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results

author_avatar
NASDAQ Market News